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Abstract
Acute myeloid leukemia (AML) is a clonal disorder of the blood forming cells characterized by accumulation of
immature blast cells in the bone marrow and peripheral blood. Being a heterogeneous disease, AML has been the
subject of numerous studies that focus on unraveling the clinical, cellular and molecular variations with the aim to
better understand and treat the disease. Cytogenetic-risk stratification of AML is well established and commonly
used by clinicians in therapeutic management of cases with chromosomal abnormalities. Successive inclusion of
novel molecular abnormalities has substantially modified the classification and understanding of AML in the past
decade. With the advent of next generation sequencing (NGS) technologies the discovery of novel molecular
abnormalities has accelerated. NGS has been successfully used in several studies and has provided an
unprecedented overview of molecular aberrations as well as the underlying clonal evolution in AML. The extended
spectrum of abnormalities discovered by NGS is currently under extensive validation for their prognostic and
therapeutic values. In this review we highlight the recent advances in the understanding of AML in the NGS era.
Introduction
Acute myeloid leukemia (AML) is the second most com-
mon hematological tumor and is characterized by increased
proliferation and impaired maturation of early myeloid
cells, leading to an accumulation of immature blood cells.
The disease is now recognized as a very heterogeneous
entity. Studies of chromosomal abnormalities by cytoge-
netics, followed by molecular genetics approach have played
a significant role in deciphering the heterogeneity of AML
as well as providing a profound insight into the biology of
leukemia. Recurrent chromosomal and molecular defects
detected at diagnosis have provided valuable prognostic
information such as: response to induction chemotherapy,
relapse risk and overall survival (OS). The 2008 WHO clas-
sification characterized AML based on recurrent genetic
abnormalities and mutations in two oncogenes (NPM1 and
CEBPA) [1]. Based on these genetic alterations, this classifi-
cation system divides patients into three categories:
favorable, intermediate and unfavorable. The cytogenetic
profile for patients with favorable prognosis includes PML-
RARA, RUNX1-RUNX1T and CBFB-MYH11 translocations.
Acute promyelocytic leukemia (APL) showing PML-RARA
are treated on ATRA- and anthracycline-based or ATRA-
and arsenic trioxide-based protocols, whereas the core bind-
ing factor (CBF) leukemias with RUNX1-RUNX1T and
CBFB-MYH11 are treated with intensive chemotherapy
involving cytarabine and are characterized by relatively
favorable prognosis [2]. Cytogenetic abnormalities asso-
ciated with unfavorable prognosis include monosomies of
chromosomes 5 or 7, 11q23 alterations (excluding t(9;11)),
inv(3), t(6;9), monosomal karyotype (defined as having
greater or equal to two autosomal monosomies or a single
monosomy with additional structural abnormalities) and
complex karyotype (presence of three or more chromoso-
mal abnormalities). These patients require allogeneic bone
marrow transplantation during their first remission. About
50% of AML patients having cytogenetically normal karyo-
type (CN-AML) are categorized in the intermediate group
[3]. Multiple mutations emerge in this group, which have
prognostic effect determining the outcome for the therapy.
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The most common mutation is NPM1 in CN-AML.
Patients having NPM1 mutation in the absence of a FLT3-
ITD mutation have better remission rate and overall survi-
val rate. On the other hand, CN-AML patients positive for
FLT3-internal tandem duplication (FLT3-ITD) have poor
prognosis [1,3]. Morphological, immunological as well as
cytogenetic evaluation of peripheral blood and bone mar-
row have been the mainstay of leukemia diagnosis. Recently
updated recommendations of the European Leukemia Net
(ELN) for the diagnosis and management of AML has been
reviewed extensively by Dohner H et al[4].
The advent of next generation sequencing (NGS) tech-
nologies has expedited the discovery of novel genetic
lesions in AML. A number of re-sequencing studies in
AML patients, particularly those showing normal cytoge-
netics, have led to the discovery of several new mutations
(including DNMT3A, IDH1, IDH2, TET2) [5]. An effort to
use the newly identified mutations, alone or in conjunc-
tion with previously characterized genetic anomalies, for
gaining prognostic insights has begun. The therapy of
AML has largely remained unchanged from the standard
3+7 regimen, for this reason the most important advances
to current prognostic markers will be identifying those
gene mutation(s) that can prospectively stratify patients
who will benefit from an allogeneic hematopoietic stem
cell transplant (HSCT). However, given the risks asso-
ciated with HSCT, the identification of underlying geno-
mic alterations in AML has a great potential for the
incorporation of rationally-targeted therapies, generating a
hope for improvement in treatment outcome. In this
review, we have outlined the recent advances in the geno-
mics of AML namely: the use of different NGS methodol-
ogies, novel mutations identified using NGS and their
clinical impact.
Next Generation Sequencing Technologies
In the past decade, conventional Sanger sequencing
method has been overtaken by several new technological
advances collectively known as next generation sequencing
(NGS). These technologies apply different target enrich-
ment strategies and clonal amplification of the DNA
resulting in the possibility of sequencing millions of DNA
strands in parallel. This massively parallel sequencing facil-
itates high-throughput sequencing with a significant
reduction in costs. The advent of NGS has significantly
accelerated the effort to understand the molecular basis of
cancers [6]. Recent development of “bench-top NGS
Instruments” such as Ion Torrent PGM from Life Tech-
nologies and Mi-Seq from Illumina has been of tremen-
dous utility in clinical settings and individual laboratories.
Ion torrent PGM is based on semiconductor sequencing
in which detection is done on a semiconductor chip. This
technology detects the pH change due to release of hydro-
gen ions when a new nucleotide is inserted during
synthesis [7]. Mi-Seq technology adopted the ‘sequencing
by synthesis’ approach in which the template amplification
and data analysis is combined in a single instrument.
These instruments are smaller in size, having high
throughput, high accuracy and less running time. In addi-
tion, these machines provide shorter read lengths which
makes them more suitable for clinical and diagnostic
applications [8]. Comprehensive reviews are available that
discuss various technological aspects of NGS and its
recent advancements [8-10].
AML Whole genome sequencing
Whole genome sequencing (WGS) based on NGS techni-
ques offers the possibility to identify the complete range of
genomic alterations: point mutations, indels, copy number
changes, and structural rearrangements including translo-
cations, cryptic rearrangements, inversions and complex
rearrangements in the whole genome. The first whole can-
cer genome to be sequenced using NGS was from an
AML patient in 2008 by Ley et al [11]. Genomic DNA
samples from tumor and skin tissues of the cytogenetically
normal AML patient were sequenced. The group per-
formed 32.7-fold ‘haploid’ coverage (98 billion bases) for
the tumor and 13.9-fold coverage (41.8 billion bases) for
the normal sample, resulting in identification of 10
somatic mutations. Out of these, two recurrent somatic
mutations (FLT3 and NPM1) have well-defined implica-
tions in AML. The other eight were somatic non-synon-
ymous novel mutations. A year later, another AML patient
with normal cytogenetics was sequenced by the same
group. They identified sixty four somatic mutations which
include mutations in the coding sequences of genes and in
the conserved regulatory portions of the genome [12]. The
identified mutations were validated in a larger cohort of
187 AML samples with recurring mutations found in
NPM1, NRAS and IDH1 genes. In a 2010 study, Ley et al
used the paired end deep sequencing approach to re-
sequence the AML samples from their first study. This led
to the identification of a recurrent somatic mutation in the
DNA methyltransferase-3-alpha gene (DNMT3A). The fre-
quency of DNMT3A mutation was 22% (62/281). They
concluded that DNMT3A mutation is a recurrent muta-
tion in patients with de novo AML classified into inter-
mediate risk category [13]. Welch et al used whole
genome sequencing to accurately diagnose an AML case
that was referred to their institute for allogeneic stem cell
transplantation. The patient had complex cytogenetic pro-
file associated with unfavorable prognosis, no detection of
PML-RARA fusion transcript by fluorescence in situ hybri-
dization (FISH) but appeared to have APL. Whole genome
sequencing was performed that led to the identification of
PML-RARA fusion gene and two other fusion genes:
LOXL1-PML and RARA-LOXL1. Finally, the patient was
treated as APL with ATRA consolidation leading to
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extended remission [14]. This was an example showing
how NGS based diagnosis could be useful in guiding clini-
cians to select the treatment path. A recent comprehensive
study by the Cancer Genome Atlas (TCGA) Research Net-
work analyzed whole genomes of 50 de novo AML cases.
This study also combined whole exome and methylome
analysis, and concluded that AML genomes have fewer
mutations than other cancers, with an average of 13 gene
mutations of which an average of 5 genes show recurrent
mutations in AML [15].
In another study using whole genome sequencing, Welch
et al compared the genomes of 12 AML M3 cases having
known initiation event (PML-RAR) vs genomes of 12 AML
M1 CN-AML patients, to identify the initiating mutation
in CN-AML [16]. It was found that both AML groups have
approximately same number of overall mutations, however,
AML M1 genomes have mutations in NPM1, DNMT3A
and IDH1 but not in AML M3. It was concluded that these
mutations might act as major initiating mutations in this
group. FLT3-ITD mutation was found in both genomes
suggesting it to be a cooperating mutation rather than an
initiating mutation. Although 13 recurrently mutated genes
were found only in AML M1 samples, there were 9 recur-
rent mutations detected in both groups suggesting coop-
eration of initiating mutations can lead to AML. This study
also proposed that most of the mutations in the AML gen-
ome are random events or exits as background mutations
in the hematopoietic stem cell. After the initiating muta-
tion event, cells expand with the same history of mutations
to become the founding clone. This clone can acquire
additional mutations to evolve into sub clones that can
contribute to disease progression or relapse. Later on, Ding
et al reported the clonal evolution of mutations in acute
and relapsed myeloid leukemia that have been reviewed
extensively elsewhere [17-19].
Transcriptome sequencing
Transcriptome sequencing is a technique that can
sequence transcribed genes, coding RNA and non-coding
RNA (ncRNA) that represents the complete transcrip-
tome. The main advantage of transcriptome sequencing
over WGS is that it provides: gene expression level infor-
mation, identification of expressed fusion transcripts, post-
transcriptional modification including alternative splicing,
single nucleotide variants (SNV) and RNA editing events
[20]. RNA Sequencing (RNA-Seq) is a recent refinement
that typically involve poly-A selection, cDNA synthesis by
reverse transcription, fragmentation followed by ligation of
sequencing primers [21]. Using paired-end RNA-Seq,
Wen et al identified novel fusion transcript in a group of
45 AML patients that included 29 CN-AML cases, 8 cases
with abnormal karyotype and 8 cases with no karyotype
information [22]. The sensitivity of RNA-Seq method was
shown by detection of well-known fusions in AML
(RUNX-RUNX1T1, MLL-MLLT1 and MLL-MLLT3) with
abnormal karyotype. Of the 134 identified fusions identi-
fied in all AML cases, seven transcript fusions were found
exclusively in CN-AML. Three CIITA-DEXI fusions on
chromosome 16 were detected in 14 out of 29 CN-AML
patients. However, this significant finding is yet to be
reproduced by other studies. Recently, Masetti et al used
transcriptome sequencing to identify two novel fusion
transcripts in pediatric CN-AML: CBFA2T3-GLIS2 fusion
and DHH-RHEBL1 fusion [23,24]. In a large cohort valida-
tion, CBFA2T3-GLIS2 transcript was recurrently found in
pediatric CN-AML cases and predicted poor outcome
[23]. The DHH-RHEBL1 transcript was detected in 40% of
CBFA2T3-GLIS2-rearranged patients and conferred even
worse prognosis than patients carrying CBFA2T3-GLIS-
rearragment [24]. Although the role of fusion transcripts
detected in this study remains to be elucidated in the
context of leukemogenesis, this study has highlighted the
possibility of using transcriptome sequencing for identifi-
cation of chromosomal aberrations even in a large hetero-
geneous group of CN-AML patients, which are otherwise
considered to be devoid of chromosomal rearrangements.
Exome Sequencing
The exome is the coding region of the genome and
accounts for only about 1% of the whole genome. Selec-
tively sequencing the exome is an effective and economic
strategy to identify novel sequence variations in the coding
region of the genome [25]. With the recent development
in high-throughput sequence capture methods, exome
sequencing has become an attractive and practical
approach for investigating coding region variations [26,27].
Several studies have been conducted to sequence the AML
exomes and the trend is increasing. Using exome sequen-
cing in nine AML-M5 patients, Yan et al identified muta-
tions in 14 genes; out of which six genes having mutations
previously implicated in cancers or other diseases are:
DNMT3A, NSD1, GATA2, CCND3, ATP2A2 and C10orf2.
The key finding in this study was the presence of three dif-
ferent DNMT3A variants in 23 out of 112 samples (20.5%),
with individuals carrying DNMT3A mutants showing
inferior prognosis as compared to ones carrying wild type
DNMT3A. In addition MLL abnormalities including MLL
translocations, NPM1 and NRAS mutations and FLT3
internal tandem duplications were also identified [28].
Grief et al sequenced three PML-RARA positive APL
patients in leukemic and remission states. APL specific
somatic mutations were identified in WT1, KRAS, HDX,
and LYN that contributes to the pathogenesis of the dis-
ease [29]. Using whole exome sequencing, Grossman et al
studied CN-AML patients with no mutation in NPM1,
CEBPA, FLT3-ITD, IDH and MLL-PTD genes (AML
index patients). Mutations in 11 genes were detected of
which the most likely candidates for AML pathogenesis
Ilyas et al. BMC Genomics 2015, 16(Suppl 1):S5
http://www.biomedcentral.com/1471-2164/16/S1/S5
Page 3 of 12
were: DNMT3A, BCOR, YY2 and SSRP1. The frequency of
BCOR mutation was 17.1% in AML index patients,
whereas the overall frequency of BCOR in unselected
CN-AML was 3.8%. Mutations in BCOR were not detected
in 131 AML cases having various cytogenetic abnormal-
ities. Interestingly, 50% of the mutated BCOR patients
have DNMT3A mutations suggesting that BCOR and
DNMT3A might have role in the pathogenesis of
CN-AML with wild type FLT3 and CEBPA [30]. Using
exome sequencing, Grief et al identified novel GATA2
zinc finger 1 mutation in 2 of 5 biallelic CEBPA
(biCEBPA) AML patients. Further mutational screening in
33 biCEBPA AML patients showed mutations in: GATA2
(39.4%), FLT3-ITD (18.2%), DNMT3A (9.1%), IKZF1
(6.1%). All mutations in GATA2 were found in the highly
conserved N-terminal zinc finger domain (ZF1 domain)
[31]. Opatz et al identified a novel N676K mutation in
fms-related tyrosine kinase 3 (FLT3) using exome sequen-
cing in core binding factor (CBF) leukemia [32]. This
study underscores the potential use of exome sequencing
in detecting novel sequence alterations even in extensively
studied genes.
Targeted next generation gene sequencing
NGS techniques are continuously evolving to decrease the
cost and time of sequencing, however, the amount of data
generated and the effort in data analysis may not be man-
ageable in a clinical diagnostic setting. On the other hand,
a full molecular diagnostic profiling of AML may be
increasingly required for clinical management of patients.
For this reason, targeted gene sequencing method has
gained popularity in recent years. This is a promising and
effective way for targeted molecular genotyping of AML
patients. Duncavage et al used targeted gene sequencing
in AML cell lines to validate a method for identifying
prognostically significant gene mutations including trans-
locations, single nucleotide variants (SNVs) and indels on
a single platform [33]. Conte et al described targeted DNA
capture method using cRNA bait combined with deep
sequencing for identification of 24 recurrently mutated
genes in CN-AML [34]. They sequenced seven AML
patients and identified 20 exonic mutations and 1 intronic
mutation in known recurrently mutated genes like FLT3,
NPM1, CEBPA, DNMT3A, TET2, IDH1 & 2, WT1 >and
KRAS. Out of these 20 exonic mutations, 11 were single
base substitutions and 9 were small indels. Two to four
mutations were present in each AML patient [34]. In a
recent study by Kihara et al, targeted NGS of 51 genes
were performed. A total of 505 mutations in 44 genes
were identified, out of which five genes: FLT3, NPM1,
CEBPA, DNMT3A >and KIT, were mutated in more than
10% of the patients [35]. In addition, this comprehensive
study analyzed the clinical features and prognostic impact
of mutations and suggested alternative risk stratification of
AML patients by inclusion of DNMT3A, MLL-PTD and
TP53 genes in the proposed European Leukemia Net
(ELN) system [35,36]. With time, advancement in targeted
gene sequencing may prove useful in clinical settings for
the detection of known chromosomal translocations and
gene mutations, requiring less procedural time and leading
to correct diagnosis and risk stratification of AML
patients.
Expanding spectrum of molecular genetic
abnormalities in AML: Implications for prognosis
and therapy
Diverse cytogenetic and molecular genetic alterations in
AML have profound influence on prognostic and thera-
peutic decisions taken by clinicians. Cytogenetic aberra-
tions at diagnosis have become well defined genetic
biomarkers for AML classification, treatment outcome
and stand as independent prognostic indicators. Core-
binding factor-acute myeloid leukemia (CBF-AML)
defined by the presence of t(8;21) or inv(16), show good
outcome with intensive chemotherapy when compared
with other AML subtypes or CN-AML [37]. Complex kar-
yotype AML (CK-AML) and AML with single autosomal
monosomies have poor prognosis, however AML patients
having multiple autosomal monosomies or autosomal
monosomies in combination with at least one chromoso-
mal structural abnormality have extremely poor outcome
[38,39]. Further prognostic stratification of poor prognosis
AML is possible with the inclusion of additional molecular
alterations. For example, CK- AML with TP53 alterations
had significantly lower complete remission (CR) rates and
worse relapse-free survival (RFS), overall survival (OS),
and event-free survival (EFS) as compared to those with-
out TP53 alterations [40]. In CBF-AML, the presence of a
KIT mutation has been shown to bring an unfavorable
influence on the outcome [41]. CN-AML that lacks these
cytogenetic profiles accounts for 40-50% of adult AML
and is the most heterogeneous sub-group of AML. Recur-
rent molecular aberrations like mutations in FLT3, NPM1,
and CEBPA have been useful in prognostic sub classifica-
tion of CN-AML and led to the inclusion of these markers
in the revised WHO classification of AML in 2008 [42].
FLT3 internal tandem duplication (ITDs) are found in
approximately 20% of all AML cases and between 28%-
34% in CN-AML [43]. AML with FLT3-ITD show worse
prognosis and is associated with shorter EFS, RFS and OS
when treated with conventional chemotherapy as com-
pared to the FLT3-ITD negative patients [3,43]. In con-
trast, patients having no FLT3-ITD but mutated biCEBPA
or NPM1 gene show favorable outcome [44,45].
With the advent of NGS technologies, several new
mutations have been described (table 1). Since then, a
number of studies have been started with the aim to
determine the mutations that contribute to disease
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pathogenesis and impact clinical outcomes. The follow-
ing novel gene mutations (summarized in table 2) have
been recently studied for their prognostic values either
independently or with other known molecular abnormal-
ities: DNMT3A, IDH1, IDH2, TET2 and ASXL1.
DNMT3A belongs to a family of DNA methylation
enzymes with three known mammalian members namely:
DNMT1, DNMT3B and DNMT3A. While DNMT1 is
responsible for maintaining DNA methylation patterns
through cell division, DNMT3A and DNMT3B are known
for de-novo methylation [46]. DNMT3A mutation is fre-
quent in CN-AML (29%-36%) [47-52]. The most common
mutation type is a missense mutation affecting amino acid
R882. AML patients showing DNMT3A mutation had
worse OS and RFS [49]. DNMT3A mutations are asso-
ciated with higher age, high WBC count and female gen-
der [50]. Marcucci G et al showed differential prognostic
impact of different types of DNMT3A mutations in older
vs younger patients: R882 mutations are associated with
adverse prognosis in older patients whereas non–R882
mutations are associated with adverse prognosis in
younger CN-AML [47]. Recent studies have demonstrated
that AML cells having R882H mutation show severely
reduced de novo methyltransferase activity and focal hypo-
methylation at specific CpGs throughout their genomes.
This activity has been attributed to the dominant-negative
inhibition of wild type DNMT3A by R882H DNMT3A
mutant that disrupts DNMT3A tetramerization [53]. A
similar finding was reported earlier from a murine
embryonic stem cell study that showed: Dnmt3a R878H
(corresponding to human R882H) mutant protein inhibits
wild-type Dnmt3a/Dnmt3b, suggesting dominant-negative
effects of mutant DNMT3a [54]. Another noteworthy fact
about DNMT3A mutation is its stability in the clonal evo-
lution of AML. In NPM1-mutated AML, Kronke et al,
demonstrated the loss of NPM1 mutation and the persis-
tence on DNMT3A mutation at relapse, suggesting
DNMT3A mutation as a founder event in AML pathogen-
esis [55]. Other studies have suggested that the stability of
DNMT3A mutations during disease progression could be
useful for monitoring residual disease [56]. Using condi-
tional ablation, Challen et al have demonstrated that
Dnmt3a loss in mice impairs long-term HSC differentia-
tion, upregulates multipotency genes and downregulates
differentiation factors in HSC [57]. Similarly, the role of
inactivating DNMT3A mutations in AML might be a key
event that shuts down differentiation of long-term HSC,
leaving the possibility of a secondary oncogenic event to
drive transformation into AML. A more recent study
demonstrates that DNMT3A mutations precede NPM1-
mutation and are found in the HSC and progenitors at
diagnosis and remission. Furthermore, this study also
Table 1 Mutations identified in Acute Myeloid Leukemia by different approaches of Next Generation Sequencing





Ley et al[11] CN-AML/M1 FLT3 (27.6), NPM1 (23.9) Indels
Mardis et al[12] CN-AML NPM1 (23.9), NRAS (9.3), IDH1 (8.5) Frame shift insertion,
missense
Ley et al[13] CN-AML DNMT3A (22.1) non-synonymous SNV





Cancer Genome Atlas Research
Network [88]
De-novo AML NPM1, FLT3, DNMT3A, IDH1, IDH2,
NRAS, RUNX1, TET2
non-synonymous SNVs
Exome Seq Yan et al[28] AML-M5 DNMT3A (20.5), GATA2 (3.6), MLL(19.6) Missense, translocation
Grossmann et al[30] CN-AML (NPM-FLT-CEBPA-
MLL-)
BCOR (17.1) disruptive mutation
Grief et al[31] BiCEBPA+ AML GATA2 (39.4) Missense mutation
Opatz et al[32] CBF leukemia FLT3-N676K (6) Missense mutation
Targeted DNA
capture
Conte et al[34] CN-AML FLT3, NPM1, CEBPA, DNMT3A, TET2,
IDH1, IDH2, WT1, RAS
Single base
substitution, indels
Transcriptome Seq Grief et al[29] AML-M1 TLE4, SHKBP1, RUNX1 Missense mutation,
Stop mutation
Wen et al[22] CN-AML CIITA-DEXI fusion transcript (14/29)
Masetti et al[23] pediatric CN-AML CBFA2T3-GLIS2 fusion transcript (8.4)
Masetti et al[24] pediatric CN-AML CBFA2T3-
GLIS2 positive
DHH-RHEBL1 fusion transcript ( 40)
Abbreviations: CN-AML: cytogenetically normal AML; CBF: core binding factor; SNV: single nucleotide variant; CN-AML (NPM-FLT-CEBPA-MLL-): CN-AML without
mutation in NPM1, FLT3, CEBPA and MLL; BiCEBPA+: biallelic CEBPAs
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Clinical characteristics Cytogenetics Association with
other mutations
Outcome
DNMT3A Roller et al
[50]
194 CN-AML 36.10% Associated with female
gender and younger age









19% Significant association with
age, gender, WBC count
75% DNMT3Amut
cases are CN-AML
NPM1 In CN-AML cases,
DNMT3A mut has




415 AML 23.10% Associated with higher






No effect on CR.
DNMT3A mut cases




415 CN-AML 34.20% Associated with higher
WBC count, BM blast
percentage
All cases are CN-
AML








29.30% No significant association
with age, sex and WBC
count
FAB M4/M5 NPM1. Inverse
association with
CEBPA.
Lower CR, shorter EFS
and OS. DNMT3A
mut with NPM1 have






17.80% Associated with old age,





NPM1, FLT3 and IDH1 Shorter OS. In CN-










Associated with older age,
high platelet counts and
blast percentage
59% of IDH mut
cases have normal
karyotype
NPM1. Not a single
IDH mut case has
CEBPA mutation












































mut belongs to FAB
M4/5
No association No difference in
survival and relapse.
CN-AML with IDH








Associated with older age,
high platelet counts










Associated with age but










34% ASXL1, TET2 and DNMT3A
mutations are associated





Shorter OS and EFS.
Additional mutation






27.40% Associated with older age
and high WBC count










486 pAML 13.20% Significant with older age,









Shorter OS in CN-
AML. No difference in
CR rate and relapse-
free survival
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demonstrates that pre-leukemic HSCs bearing DNMT3A
mutation generate multilineage engraftment and have a
competitive advantage in the immunodeficient mice-based
repopulation assays [58]. These recent studies not only
suggest DNMT3A mutation as a potential therapeutic tar-
get and a marker for tracking residual disease, but also as
a marker for pre-leukemic clones [56,58].
Another epigenetic modifier mutated in AML is isoci-
trate dehydrogenase (IDH) enzyme. IDH family has three
different isoforms: IDH1, IDH2 and IDH3 which take part
in the metabolic Krebs cycle. IDH1 is localized in the cyto-
plasm. IDH2 and 3 are present in mitochondria, and these
three enzymes catalyze the oxidative decarboxylation of
isocitrate to alpha ketoglutarate (a-KG) [59]. IDH1 muta-
tion was recurrently found in 16% of CN-AML [12]. IDH2
mutation was also reported in AML by candidate gene
sequencing study [60]. Recurrent mutations were found in
codon R132 in the case of IDH1 and at codon R140 or
R172 in case of IDH2, resulting in gain of function of
these enzymes which reduce a-KG to oncometabolite
2-hydroxyglutarate (2-HG) [61]. 2-HG was found to be
elevated in the serum of AML patients carrying IDH
mutations, and the level of this oncometabolite may be
useful as a diagnostic and prognostic indicator [62]. The
prognostic impact of IDH mutations in AML has been
investigated by several studies. In CN-AML patients, IDH
mutations were associated with adverse OS and disease
free survival (DFS). In CN-AML with a favorable genotype
(NPM or CEBPA mutated/FLT3 wt), IDH mutations were
associated with poor outcome [60,63-65], thereby indicat-
ing a possibility of further refinement of this subgroup of
CN-AML. In addition to their diagnostic and prognostic
values, IDH mutations have been recognized as important
therapeutic targets. Recently, Wang et al used AGI-6780,
a novel and selective inhibitor of mutant IDH2 to induce
differentiation in TF-1 (an erythroleukemia cell line) and
primary AML cells [66]. In another study, an inhibitor of
mutant IDH1, AGI-5198, has been shown to delay growth
and induce differentiation of glioma cells [67], providing a
proof-of-concept that IDH mutants can be therapeutically
targeted. Phase I clinical trials are ongoing with two orally
available, selective, potent inhibitors IDH: AG-221 (for
IDH2) and AG-120 (for IDH1) [68,69].
Mutation in the Ten-Eleven Translocation 2 (TET2)
gene was found in 24% of AML and also in other mye-
loid cancers [70]. TET2 is the member of TET family of
dioxygenases that convert 5-methyl-cytosine (5-mC) to
5-hydroxymethyl-cytosine (5-hmC) [71]. 5-hmc plays an
important role in DNA demethylation. TET2 mutations
were found to be significant with older age, high WBC
and associated with other genetic alterations like IDH1
mutations in CN-AML. Patients with TET2 mutations
have shorter OS and lower CR rate [72]. Chou et al
using mutational screening of primary AML patients




427 CN-AML 23% Associated with older age,
high WBC count





Shorter EFS and DFS,




247sAML 19.80% Associated with male
gender, old age and
platelet counts













5.30% Associated with old age
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demonstrated TET2 mutation as an unfavorable prog-
nostic factor in AML with intermediate cytogenetics
[73]. A study with younger adult AML patients with
TET2 mutations in 7.6% cases found no influence of
these mutations on the response to therapy and survival.
In addition, TET2 mutations were found to be mutually
exclusive with IDH mutations [74]. Comparing de novo
and relapse stages of AML, Wakita et al demonstrated
that mutations in the epigenetic modification genes
(DNMT3A, TET2 and IDH) are stably present at diagno-
sis and relapse suggesting them as potential biomarker
in minimal residual disease (MRD) monitoring [75].
Mutations in genes that effect posttranslational modifi-
cation of histones have been well known in AML through
MLL1 gene aberrations that include translocations and in-
frame duplications [76]. Mutations in ASXL1, a member
of Polycomb group of proteins have been observed fre-
quently in myelodysplastic syndromes, chronic myelomo-
nocytic leukemia and AML [77-79]. Schnittger et al
recently observed that ASXL1 mutations are more fre-
quent in intermediate risk aberrant karyotype AML (31%)
than in CN-AML (12.5%). Patients with ASXL1 mutations
had shorter OS and EFS. In addition, ASXL1 mutation
appeared as an independent adverse factor for OS in mul-
tivariate analysis [80]. An earlier study by Metzeler et al
demonstrated that ASXL1-mutated older AML, particu-
larly those within ELN Favorable group have adverse clini-
cal outcomes [81]. Although the biological function of
ASXL1 is not fully understood, a number of physical inter-
actions with several proteins have been uncovered.
A recent study by Abdel-Wahab et al showed that hema-
topoietic-specific deletion of Asxl1 resulted in an increase
in the number of hematopoietic stem and progenitor cells
(HSPC) and caused a progressive myelodysplasia that was
transplantable. It was shown that Asxl1 loss resulted in a
global reduction of H3K27 trimethylation and aberrant
expression of known hematopoietic regulators [82], raising
the possibility of using H3K27 demethylase inhibitors in
this situation.
Conclusion and future directions
Recent high throughput NGS approaches have uncovered
a number of novel genetic alterations. The main challenge
is to integrate this knowledge into clinical management of
AML. As highlighted in the sections above, a number of
novel molecular mutations have been validated in studies
with large number of AML patients and subsequently
being used in prognostic subclassification of AML.
DNMT3A, TP53 and MLL-PTD mutations, for example
have been recently suggested to refine the ELN classifica-
tion of AML [35]. Likewise, TET2 and ASXL1 have been
suggested as candidate markers for improvement of CN-
AML classification in ELN scheme [72,81]. Prospective
and large-scale studies are needed to clarify the influence
of many of these novel molecular aberrations in conjunc-
tion with well characterized prognosticators (NPM1,
FLT3-ITD and CEBPA), on prognosis of AML.
The application of NGS in clinical settings is limited by
certain challenges such as: technical difficulties in capture
of GC-imbalanced targets, inaccurate reading of repetitive
genomic regions and time-consuming data analysis that
need special bioinformatics skills. In addition, there is a
lack of uniform practice for quality assessment of NGS
data. A collaborative approach among scientists, bioinfor-
maticians and physicians coupled with creation of easily
accessible and understandable database will greatly
enhance and ease the clinical application of NGS.
The NGS based AML sequencing has provided several
biological insights into the pathogenesis of leukemia. One
key lesson derived from these studies, owing to the simul-
taneous detection of the whole plethora of mutations in
cells, is the cancer genome evolution. Paired analysis of
diagnosis and relapse samples have revealed marked
changes in the genetic makeup of the cells between these
points [17]. It is now understood that in AML multiple
subpopulations of genetically heterogeneous cells co-exist.
Competition among the subpopulations that harbor driver
events thus drives the evolution of cancer either in a linear
trajectory, a branched trajectory, or a combination of both,
eventually shaping the final tumor composition [18,19].
A better understanding of the AML genome evolution is
needed. This will help in understanding the mechanisms
of relapse, provide information about driver and cooperat-
ing events, improve the understanding of recurrent pat-
terns of therapy resistance and suggest appropriate
molecular targets.
One way to understand the pathogenic relevance of
novel genetic alterations is to perform functional studies
in animal models. A number of studies have taken this
approach recently in evaluating the role of: Asxl1 [82],
Tet2 [83] and Dnmt3a [57]. However, many recently iden-
tified genetic alterations, including novel chromosomal
translocations remain to be studied in detail. Exhaustive
functional studies using in vitro and in vivo experimental
models are needed to understand the biological signifi-
cance of these novel alterations and to distinguish driver
events from passenger events. In addition, these models
would pave the way for preclinical studies including test-
ing novel therapeutic interventions.
Identification of high frequency of mutations in potential
epigenetic regulators (DNMT3A, TET2, IDH1, IDH2,
ASXL1, and UTX) is particularly interesting. It remains
imperative that the mechanisms underlying epigenetic dys-
regulation and its consequences be clearly understood.
This may allow us to better use the available methylation
and histone deacetylase (HDAC) inhibitors based on the
underlying genetic abnormalities that have shown some
clinical success in the treatment of myeloid leukemias
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[77,84]. Many new drugs that target aberrant but reversi-
ble epigenetic modifications have been recently tested in
preclinical leukemia models and leukemia cell lines:
Schenk et al recently demonstrated that inhibitors of
lysine-specific demethylase 1 (LSD1, also known as
KDM1A) epigenetically reprogram the cells to make them
sensitive to ATRA induced differentiation in AML [85]. A
study by Deshpande et al demonstrated how inhibition of
histone-methyltransferase DOT1L, that is the driving force
behind MLL-AF6 fusion leukemias, resulted in inhibition
of MLL-AF6-transformed cells [86]. Stewart et al demon-
strated how targeting bromodomain containing protein 4
(BRD4) in combination with daunorubicin inhibited
growth of DNMT3A/NPM1-mutated leukemia cells [87].
These studies stress the potential of targeted therapies
against the expanding spectrum of mutations in AML.
The progressive enhancement in the molecular charac-
terization of AML holds promise for undertaking the
more precise and targeted therapeutic strategies leading to
possibly better treatment outcomes. In addition to this,
inclusion of NGS based deep sequencing methods in
molecular diagnostics workup has the potential to realize
the goals of personalized medicine.
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